Associations between industry sponsorship and results of cost-effectiveness analyses of drugs used in breast cancer treatment
A partir d'une revue de la littérature publiée entre 1991 et 2012, cette étude analyse l'association entre des financements d'études par l'industrie pharmaceutique et leurs résultats en matière de rapport coût-efficacité de divers traitements du cancer du sein
This study describes the association between pharmaceutical industry–sponsored studies and findings from cost-effectiveness analyses of drugs used in breast cancer treatment. A 1999 investigation found that industry sponsorship of cost-effectiveness analyses (CEAs) for oncology drugs was associated with lower likelihood of reporting unfavorable conclusions relative to CEAs with other sponsorship. Over the past 15 years, the CEA literature for oncology drugs has expanded dramatically, and oncology now accounts for the largest single pharmaceutical sales area worldwide. We sought to determine whether the association between industry sponsorship and CEA results has persisted.